PharmaEssentia (6446) Q2 2025 earnings summary

Executive summary

• Achieved strong revenue growth for the six months ended June 30, 2025, with significant increases in both product sales and net income year-over-year.

• Maintained robust cash and cash equivalents position, supporting ongoing R&D and expansion initiatives.

• Resolved key arbitration with AOP Orphan Pharmaceuticals, with most claims dismissed and some liabilities recognized, but compensation amounts remain undetermined.

• Continued investment in clinical trials, manufacturing expansion, and licensing agreements to support future growth.

Financial highlights

• Operating revenue for H1 2025 was NTD 6,859,767 thousand, up 73% year-over-year.

• Net income for H1 2025 reached NTD 2,095,808 thousand, more than double the prior year period.

• Gross margin for H1 2025 was 88%, consistent with prior year.

• Basic EPS for H1 2025 was NTD 6.30, compared to NTD 3.05 for H1 2024.

• Cash and cash equivalents as of June 30, 2025 were NTD 20,782,747 thousand.

Outlook and guidance

• Ongoing expansion of manufacturing capacity, including new Zhubei plant construction, to meet global demand.

• Continued focus on global clinical trials and regulatory approvals for pipeline products.

• Strategic capital allocation to support R&D, licensing, and international market entry.